A Phase 1 Study of TLN-372 in People With Advanced Solid Tumors

Full Title

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination with Other Anti-Tumor Agents, in Patients with Advanced KRAS Mutant Solid Tumors

Purpose

Researchers want to find the best dose of TLN-372 in people with advanced solid tumors. The people in this study have cancer that has spread and has a mutation in the KRAS gene.

TLN-372 may help slow or stop the growth of your cancer by blocking the KRAS protein. 

Contact

For more information about this study or to see if you can join, please call 646-888-4226.